ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

PHASE3CompletedINTERVENTIONAL
Enrollment

614

Participants

Timeline

Start Date

September 22, 2016

Primary Completion Date

October 15, 2021

Study Completion Date

February 22, 2024

Conditions
Ovarian Cancer
Interventions
DRUG

atezolizumab + avastin + platinum-based chemotherapy

"* atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"

DRUG

placebo + avastin + platinum-based chemotherapy

"* placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"

Trial Locations (75)

1090

Medical University of Vienna, Vienna

3000

Uz Leuven, Leuven

6020

Medical University of Innsbruck, Innsbruck

7120

Hospital Universitario Son Espases, Palma de Mallorca

8020

Krankenhaus der Barmherzigen Brüder Graz, Graz

8036

Medical University of Graz, Graz

Hospital Clínic Barcelona, Barcelona

9000

UZ Gent, Ghent

10003

Hospital San Pedro de Alcántara, Cáceres

17007

Hospital Universitari de Girona ICO Girona (Dr. Josep Trueta), Girona

20014

Hospital Universitario Donostia, San Sebastián

28040

Hospital Universitario Clínico San Carlos, Madrid

28046

Hospital Universitario La Paz, Madrid

28050

Hospital Universitario HM Sanchinarro, Madrid

30120

Hospital Central Universitario Virgen de la Arrixaca, Murcia

36312

Hospital Alvaro Cunqueiro, Vigo

41009

Hospital Universitario Virgen Macarena, Seville

45136

Kliniken Essen Mitte, Evang. Huyssens-Stiftung, Essen

67550

Klinikum Worms, Worms

72076

Universitatsklinikum Tübingen, Tübingen

128 51

General University Hospital in Prague, Prague

Unknown

ICO Paul Papin, Angers

Sainte-Catherine Institut du Cancer Avignon-Provence, Avignon

CHRU Jean Minjoz, Besançon

Clinique Tivoli, Bordeaux

Institut Bergonié, Bordeaux

Centre François Baclesse, Caen

Centre Jean Perrin, Clermont-Ferrand

Groupe Hospitalier Mutualiste de Grenoble, Grenoble

Hôpital Michallon - Centre Hospitalier Universitaire de Grenoble, Grenoble

Centre Hospitalier Départemental Les Oudairies, La Roche-sur-Yon

Centre Oscar Lambret, Lille

Centre Léon Bérard, Lyon

Institut Paoli Calmettes, Marseille

Hôpital de Mont-de-Marsan, Mont-de-Marsan

ICM Val d'Aurelle, Montpellier

Centre Azuréen de Cancérologie, Mougins

ORACLE - Centre d'Oncologie de Gentilly, Nancy

Hôpital Privé du Confluent, S.A.S., Nantes

Centre Antoine Lacassagne, Nice

CHU Nîmes - Institut de Cancérologie du Gard, Nîmes

Centre Hospitalier Régional d'Orléans, Orléans

Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris

Groupe Hospitalier Saint-Joseph, Paris

Hôpital Cochin, Paris

Hôpital Européen Georges Pompidou, Paris

Hôpital Tenon, Paris

Institut Curie - Hopital Claudius Régaud, Paris

Centre Hospitalier Lyon Sud, Pierre-Bénite

Centre CARIO - HPCA, Plérin

Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers - Pôle Régional de Cancérologie, Poitiers

Centre Eugène Marquis, Rennes

Hôpital René Huguenin, Institut Curie, Saint-Cloud

ICO Centre René Gauducheau, Saint-Herblain

Centre Paul Strauss, Strasbourg

Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg

Clinique Pasteur, Toulouse

Institut Claudius Regaud, Toulouse

ICL Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

Gustave Roussy, Villejuif

Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin

Universitätsklinikum Carl Gustav Carus, Dresden

Universitatsklinikum Dusseldorf, Düsseldorf

Universitätsklinikum Essen, Essen

Universitätsklinikum Hamburg-Eppendorf, Hamburg

Medizinische Hochschule Hannover, Hanover

Universitätsklinikum Jena, Jena

Städtisches Klinikum Karlsruhe, Karlsruhe

Klinikum der Universität München - LMU, Campus Großhadern, München

Klinikum rechts der Isar, Technischen Universität München, München

Sana Klinikum Offenbach, Offenbach

Studienzentrum Onkologie Ravensburg, Ravensburg

Universitätsklinikum Ulm, Ulm

Sharre Zedek Medical Centre, Jerusalem

08035

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

ARCAGY/ GINECO GROUP

OTHER

NCT02891824 - ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab | Biotech Hunter | Biotech Hunter